All News
Inferior IL-17 Inhibitor Responses in Psoriatic Women
Pooled data from two large ixekizumab (IXE) trials show that male patients had greater clinical responses than did female patients with psoriatic arthritis are largely unexplored. Reasons for this differential treatment responses to an interleukin-17A inhibitor (IXE) between male and female patients is unexplained.
Read Article
Of the Top 20 most expensive drugs in USA in 2022, only two are for rheumatic reasons. Unfortunately both are for ACTH preparations, once cheap, now devastatingly expensive: #11 Acthar Gel ($41,459/month) & #19 Cortrophin Gel ($30,083) https://t.co/avUZNVnHRp https://t.co/mXLhD8vJ6A
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of new onset #RA & undiff arthritis pts starting Rx 2005-2010; mean F/U 104 mos, 11% died. Steroids (<7.5/d) given to 44% initially, ultimately 57% w/ 20% recv >7.5/d. Steroids did not increase mortality (HR 1.35 ; 0.74, 2.47) or hospitalization https://t.co/KNpobs1UwH https://t.co/sjddMBKOeE
Links:
Dr. John Cush RheumNow ( View Tweet)
A reflex slide I put together for you. https://t.co/HMumN7WaJY
Oren Gottfried, MD OGdukeneurosurg ( View Tweet)
Renal Tubular Disorders #NephTwitter #MedEd #MedDoodles https://t.co/KiCuEaDGrR
Sarah Lyon sarahthelyon ( View Tweet)
It's time to exonerate methotrexate in causing or exacerbating fibrotic interstitial lung disease in #RA patients https://t.co/AuEIWn8Pc4 https://t.co/razVTF6fFX
Links:
Dr. John Cush RheumNow ( View Tweet)
Simultaneous Versus Staged Knee Arthoplasty?
There are an estimated 900,000 knee replacements (TKR) performed in the U.S. every year. This number is up from 754,000 TKRs in 2017, according to the Agency for Healthcare Research and Quality.
https://t.co/KuLEaI3r0d https://t.co/0q1RBsDwEM
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA approved Abbvies risakizumab-rzaa (Skyrizi) as the 1st interleukin-23 inhibitor for use in adults with moderately to severely active Crohn's disease (600 mg IV at wk 0, 4, 8, &q8wk @ 360 mg SC). Approval based on ADVANCE, MOTIVATE & FORTIFY RCTs https://t.co/OMYNB1yr2R https://t.co/QMn9GWlYm9
Links:
Dr. John Cush RheumNow ( View Tweet)
JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway? Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases. https://t.co/SvkcZwqzBo https://t.co/M3BkoF4amb
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 7 studies shows that oral anticoagulants need not be discontinued for joint injections or aspiration. Only pts w/ hemorrhage after 5427 procedures, over 32-yrs. INR values of 3 bleeding cases was 1.9, 2.3, and 3.4. https://t.co/pCxDqzXGHQ https://t.co/ExZkXSliFo
Links:
Dr. John Cush RheumNow ( View Tweet)
Modest Benefits of Diet on Arthritis
A EULAR taskforce reviewed the literature on the effects of diet and lifestyle behaviors in RMDs, and found little evidence suggesting dietary factors can substantially affect the outcomes in people with RMDs.
https://t.co/D31l7dlq9v https://t.co/Kt80Yp74ro
Links:
Dr. John Cush RheumNow ( View Tweet)
#Leadership = serving your team, being the fall guy, getting group through crazy unnecessary beaurocracy, and loving something about each member of the group. Having their back, sacrificing for them. I can only strive to lead....
Janet Pope Janetbirdope ( View Tweet)
Treatment of pyoderma gangrenosum is clinically empiric. Full read ref w/ Graded Rx Recommendations:
- 1st line: Steriods or Cyclosporin
- Consider biologics: TNFi, IL-1, IL-12/23, IL-17, IL-23
- Others: MTX, MMF, AZA, Dap, colchic, thalidomide, IVIG https://t.co/uMJyfFzsRB https://t.co/vw4VqbjZWh
Links:
Dr. John Cush RheumNow ( View Tweet)
Multinational recs. on Rx of JIA assoc. Uveitis:
- Topical steroids are 1st line Rx
- Systemic Rx if above fails or w/ poor prognosis or persistence
- Options MTX, MMF then Humira EOW, then weekly ADA
- Consider non-ETN TNFi's, then TCZ, ABA, JAKi or RTX https://t.co/ZfVeWf5sVg https://t.co/yu3to0LdEd
Links:
Dr. John Cush RheumNow ( View Tweet)
Podcast on Podcasting
A tutorial on podcasting - what works and what does not.
https://t.co/QINseXd6Z2 https://t.co/OFuVacgcfq
Links:
Dr. John Cush RheumNow ( View Tweet)
Environmental articulate matter (PM2.5) levels can increase the odds of a systemic autoimmune rheumatic disease onset (OR 1.12; 1.08–1.15), , w/ no effect of ozone. Results not changed by controlling for smoking. https://t.co/7BGBh9h0lf https://t.co/LcUo4Lxzgx
Links:
Dr. John Cush RheumNow ( View Tweet)
Axial PsA: Is it for Real?
Dr. Janet Pope ( @Janetbirdope) presenting from EULAR 2022.
https://t.co/0smaACel5k https://t.co/UJ3hi3rJlY
Links:
Dr. John Cush RheumNow ( View Tweet)
Lupus Research Alliance’s has awarded the Lupus Insight Prize to Akiko Iwasaki, PhD (professor at Yale School of Medicine) for her research on the pathogenic role of retroviruses in lupus published in Journal of Experimental Medicine https://t.co/xmQjFLk63K https://t.co/68Ezlfk00j
Links:
Dr. John Cush RheumNow ( View Tweet)
Lower Fx risk in PsA Rx w/ biologics? Review of 100 RCTs, 51,413 Pso & PsA pts; pts on bDMARDs had signif lower risk of major OP Fx (OR 0.34), hip Fx (OR 0.22) & OP non-vertebral Fx (OR 0.26). Fx risk not changed in RA, axSpA, SLE, IBD pts on biologics https://t.co/Acv1q1K5A9 https://t.co/dAaq2EsTDK
Links:
Dr. John Cush RheumNow ( View Tweet)
RWE & Registries in Psoriatic Arthritis
Dr. Alexis Ogdie presents RWE & Registries in Psoriatic Arthritis at the 2022 RheumNow Live meeting.
https://t.co/zYcDrhgbNr https://t.co/s4Hv3ub9Av
Links:
Dr. John Cush RheumNow ( View Tweet)
